1. Scrip
  2. >>Business
  3. >>Strategy

Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko

 
• By Joseph Haas

Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.

Cell mitochondria
Astellas' recent deals include the buyout of Nanna and its mitochondrial modulation expertise

Astellas Pharma, Inc., the multinational biopharma headquartered in Tokyo with multibillion-dollar operations in the US, was impacted by the same forces that buffeted many in the industry in 2020, including the global COVID-19 pandemic. The global health crisis delayed and, in some cases, halted ongoing projects at Astellas but it also offered new business opportunities and revealed novel ways to work and collaborate.

Astellas Pharma US Inc. President Percival Barretto-Ko oversees the company’s US operations from its base in Northbrook, IL. The...

More from Strategy

More from Business

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 
• By Anju Ghangurde

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.